Successful Management of HFpEF-Related Pulmonary Hypertension With Systemic-Level Pressures Using Sacubitril-Valsartan and Empagliflozin.

Background: Pulmonary hypertension (PH) is present in over two-thirds of patients who experience heart failure with preserved ejection fraction (HFpEF), and it worsens their prognosis, particularly when combined with right ventricular dysfunction. Effective treatments for HFpEF-related PH are limited.

Case Summary: A 70-year-old woman presented with severe exertional dyspnea and hypoxia.

Long-term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices.

Aims: HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility-related outcomes for end-stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin. This study presents a long-term evaluation of thrombotic and bleeding outcomes in HM3 LVAD patients transitioned from warfarin to apixaban.

Methods: We retrospectively identified HM3 LVAD patients at our single centre who transitioned from warfarin to apixaban.